Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study [0.03%]
stereotactic ablative radiotherapy联合纳武利尤单抗治疗早期非小细胞肺癌的病理反应：一项II期研究
Gustavo Schvartsman,Yasmin M Amirato,Frederico Monfardini et al.
Gustavo Schvartsman et al.
Introduction: Stereotactic ablative radiotherapy (SABR) is routinely used in patients with early stage NSCLC who are not candidates for surgery. Despite excellent local tumor control, it is associated with a high rate of ...
Curative-Intent Multimodality Treatment for NSCLC: Will Global Healthcare Systems Rise to the Challenge? A Perspective From the United Kingdom [0.03%]
带着治愈的目的对NSCLC进行多模式治疗：全球医疗体系能否迎接挑战？英国专家观点
Matthew Evison,Shobhit Baijal,Mayuri Basnet et al.
Matthew Evison et al.
Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA) [0.03%]
澳大利亚阳性晚期NSCLC的治疗模式、预后因素和生存率：来自澳新地区胸部肿瘤登记队列研究及生物样本库(AURORA)的结果
Grace Chazan,Marliese Alexander,Fanny Franchini et al.
Grace Chazan et al.
Introduction: Advanced lung cancer has historically been associated with poor survival. However, with the advent of targeted therapies, outcomes are improving. Among patients with ALK-rearranged advanced NSCLC (ALK+ aNSCL...
Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches [0.03%]
胸腺神经内分泌肿瘤：新兴的见解和创新方法
Erica Pietroluongo,Christine M Bestvina,Rachel Brattin et al.
Erica Pietroluongo et al.
Introduction: Thymic neuroendocrine tumors (TNENs) are exceptionally rare and a clinically heterogeneous malignancy, often diagnosed at an advanced stage and lacking standardized treatment algorithms. Due to the scarcity ...
The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC [0.03%]
NSCLC中CEACAM5的免疫组化表达谱分布
Ying-Han R Hsu,Amna Almutrafi,Katrina Hueniken et al.
Ying-Han R Hsu et al.
Introduction: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients wit...
FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors [0.03%]
FDG-PET/CT SUVmax可预测肺源性孤立性纤维肿瘤术后复发风险
Matthew Aizpuru,Jennifer M Boland,Brendan W Lunn et al.
Matthew Aizpuru et al.
Objectives: Risk stratification of pleuropulmonary solitary fibrous tumors (SFTs) is based on post-resection histopathologic scoring systems. We queried whether preoperative 18-fluorodeoxyglucose positron emission tomogra...
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report [0.03%]
携带ALK重排的NSCLC患者继发组织学转化SCLC对Tarlatamab治疗反应首次报道：个案报告
Kaiwen Wang,Ceylan Altintas Taslic,Patricia de Groot et al.
Kaiwen Wang et al.
Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with EGFR-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including ALK-rearranged ...
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial [0.03%]
Trodelvy治疗转移性NSCLC的患者报告症状和生活质量：EVOKE-01 III期随机对照研究
Niels Reinmuth,Sébastien Couraud,Luis Paz-Ares et al.
Niels Reinmuth et al.
Introduction: In the phase 3 EVOKE-01 trial (NCT05089734), sacituzumab govitecan (SG) exhibited a numerical improvement in overall survival and tolerability compared with docetaxel in patients with metastatic NSCLC previo...
Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data [0.03%]
国际肺癌研究协会对美国临床肿瘤学会癌症数据的分析：NSCLC患者的生物标志物检测和治疗模式.linspace发现数据）
Madhusmita Behera,Gregory Joseph,Manali Rupji et al.
Madhusmita Behera et al.
Introduction: Precision medicine has resulted in improved outcomes for non small cell lung cancer (NSCLC), whereas biomarker testing is considered critical for guiding treatment decisions for advanced-stage NSCLC, and ado...
Unmasking the Hidden Cardiopulmonary Cost of Lobectomy: A Paradigm Shift Demanded by Exercise Hemodynamics [0.03%]
揭开肺叶切除隐藏的心肺代价：运动血液动力学要求的范式转换
Qiang Wu,Zhenyang Lv,Zhe Fan et al.
Qiang Wu et al.